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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).SUMMARY valuable for dissecting complex gene-environmental interac-Parkinson’s disease (PD) has been attributed to a
combination of genetic and nongenetic factors. We
studied a set of monozygotic twins harboring the
heterozygous glucocerebrosidase mutation (GBA
N370S) but clinically discordant for PD. We applied
induced pluripotent stem cell (iPSC) technology
for PD disease modeling using the twins’ fibro-
blasts to evaluate anddissect the genetic and nonge-
netic contributions. Utilizing fluorescence-activated
cell sorting, we obtained a homogenous population
of ‘‘footprint-free’’ iPSC-derived midbrain dopami-
nergic (mDA) neurons. The mDA neurons from both
twins had 50% GBA enzymatic activity, 3-fold
elevated a-synuclein protein levels, and a reduced
capacity to synthesize and release dopamine.
Interestingly, the affected twin’s neurons showed an
even lower dopamine level, increased mono-
amine oxidase B (MAO-B) expression, and impaired
intrinsic network activity. Overexpression of wild-
type GBA and treatment with MAO-B inhibitors
normalized a-synuclein and dopamine levels, sug-
gesting a combination therapy for the affected twin.
INTRODUCTION
Monozygotic (MZ) twins exhibit marked phenotypic similarities
due to their shared genetic makeup. Twin studies have beenCell Retions in neurodegenerative disorders. In a study of twins in the
United States, the concordance of MZ twins developing Parkin-
son’s disease (PD) is 15.5%, whereas the concordance of dizy-
gotic (DZ) twins is 11.1% (Tanner et al., 1999). A twin study in
Sweden found a concordance rate for PD was 11% in MZ pairs
and 4% for DZ pairs (Wirdefeldt et al., 2011). This demonstrates
that PD is moderately heritable, in agreement with observations
that familial PD cases are relatively uncommon (10%) and that
even monogenic forms of PD have reduced penetrance. We
recently recruited a pair of MZ twins discordant for PD 5 years
after diagnosis of the affected twin. The presented work details
our efforts to evaluate the genetic and epigenetic insults that
might potentially explain the discordant onset of PD in twins.
Homozygous or compound heterozygous glucocerebrosidase
(GBA, GCase) mutations cause Gaucher disease, a lysosomal
storage disorder. Recently, GBA mutations have been linked to
a 5-fold greater risk of developing parkinsonism than noncarrier
individuals (Sidransky et al., 2009) and are themost common ge-
netic risk factor for PD to date. In GBA-PD patients, the clinical
phenotypes are similar to those of idiopathic PD cases, except
for the occurrence of more-severe nonmotor symptoms, partic-
ularly cognitive decline. Postmortem examination of GBA-PD
patients shows a-synuclein pathology (i.e., Lewy bodies) with a
loss of dopaminergic neurons in the substantia nigra.GBAmuta-
tions might potentially lead to PD pathology by increasing a-syn-
uclein aggregation (Mazzulli et al., 2011) or defective mitochon-
drial turnover (Osellame et al., 2013). It has been proposed that
introduction of exogenous wild-type (WT) GBA could rescue
these PD-related phenotypes (Cullen et al., 2011; Sardi et al.,
2011). The penetrance of PD in GBA mutation carriers isports 9, 1173–1182, November 20, 2014 ª2014 The Authors 1173
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approximately 30% by the age of 80, but a significant proportion
of carriers will never develop PD during their lifetime (Anheim
et al., 2012). It is unclear why a subset ofGBAmutations carriers
would develop PD whereas others do not. Evidence suggests
that complex genetic and environmental factors confer the addi-
tional risks of PD development.
Induced pluripotent stem cell (iPSC) technology offers a
unique opportunity to study genetic and epigenetic risk factors
present in patient-specific midbrain dopaminergic (mDA) neu-
rons compared to those from healthy controls. Dopaminergic
neurons from genetic PD cases have been used to recapitulate
relevant disease pathology, including a-synuclein accumulation,
impaired dopamine (DA) release, mitochondrial dysfunction,
vulnerability to oxidative stress, and increased ERK phosphory-
lation (Cooper et al., 2012; Devine et al., 2011; Jiang et al., 2012;
Mazzulli et al., 2011; Nguyen et al., 2011; Reinhardt et al., 2013;
Sa´nchez-Dane´s et al., 2012). Despite these findings, variability in
differentiation efficiency and neuronal maturity pose major ob-
stacles for PD disease modeling.
In this report, using iPSC technology, we investigated the
unique set of MZ twins and found that a-synuclein clearance is
impaired in mDA neurons carryingGBAN370S regardless of dis-
ease status. Elevated monoamine oxidase B (MAO-B) level
could in part explain the degree of impairment in DA production
between mDA neurons derived from the MZ twins discordant for
PD. Importantly, overexpression of GBA and inhibition of MAO-B
activity rescued a-synuclein accumulation and DA release phe-
notypes. These results suggest that a ‘‘multiple hit’’ process
eventually contributes to reduced dopamine production, a pa-
thology that could be rescued by a combination approach
against a-synuclein and MAO-B.
RESULTS
Genetic Analysis Reveals the GBA N370S in the
MZ Twins
We recently identified a pair of 68-year-old, MZ male twins of
Ashkenazi Jewish background who are discordant for PD. The
affected twin had been diagnosed with PD at age 63. His MZ
twin has no signs or symptoms of parkinsonism after detailed ex-
amination by a movement disorders specialist (Table S1). Short
tandem repeats analysis confirmed that they are monozygotic
(Figure S1A). We screened their skin fibroblasts for 66 known
PDgeneticmutations (Marder et al., 2010). Both twinswere found
to carry heterozygous GBA N370S, an established genetic risk
for PD. Whole-exome sequencing of fibroblasts displayed that
39,300 single-nucleotide variants (SNVs) were called and 96%
of SNVs were shared in both pairs (Figure 1A; Table S2). Cross-Figure 1. Characterization of FACS-Isolated Neurons from a Cohort of
(A) Whole-exome sequencing the fibroblasts derived from twins.
(B) Diagram depicts two panels of antibodies at two time points to isolate mDA p
(C) FACS analysis of the neuronal differentiation before purification (n = 611).
(D) Percent of TH/TUJ1-positive cells in sorted CD56+/CD24+/CD15/CD184 p
(E) Phase-contrast image of sorted cells 3 days post-FACS and immunofluoresc
(F) Quantitative gene-expression analysis in iPSCs, mDA procursors, unsorted n
(G and H) Immunofluorescence for TH, FOXA2, TUJ1, LMX1, PITX3, MAP2, and
scale bars represent 50 mm (E) and 25 mm (G and H).
Error bars represent SEM.
Cell Rereferencing with the PD gene databases (Do et al., 2011; Lill
et al., 2012), we identified 82 PD-related SNVs (Table S3). Among
these variants,GBAN370S exhibited a significantly high odds ra-
tio (odds ratio= 3.4).DNA-sequencing chromatographs showeda
clear heterozygous mutation (c.1226 A > G; Figure S1B).
iPSC-Derived mDA Neurons Are Enriched Using a
Combination of Cell-Surface Markers
Next, we investigated potential molecular mechanisms respon-
sible for PD in dopaminergic neurons derived from fibroblasts
of the affected twin, unaffected twin, a subject with sporadic
PD, and four healthy subjects (Table S1). We used Sendai virus
reprogramming to generate transgene-free iPSC lines, all well
characterized in Figures S2A–S2G.
Utilizing the neuronal differentiation protocol (Kriks et al.,
2011), we produced mDA progenitors and mDA neurons from
the iPSC lines listed above. After the 11-day differentiation,
most cells expressed SOX1 (mDA progenitors marker), FOXA2,
and LMX1 (midbrain markers; Figure S2H). Further neuronal dif-
ferentiations gave rise to substantia nigra (A9) dopaminergic
neurons by expression of TUJ1 (panneuronal marker), TH (DA
neuronal marker), and GIRK2 (A9 neuronal marker). In patch-
clamp recordings, iPSC-derived neurons fired action potentials
in response to injected current, exhibiting voltage-gated sodium
and potassium currents (Figure S2I), and also showed sponta-
neous firing (Figure S2J), suggesting that these mDA neurons
were physiologically active.
Differentiated cultures yield 5%–15% mDA neurons (Salti
et al., 2013). When characterizing lines, this low yield seemed
to exaggerate phenotypic differences. To overcome this prob-
lem, we developed an approach to generate midbrain neuron-
enriched preparations by fluorescence-activated cell sorting
(FACS). Using a combination of surface markers specific to
iPSCs, mDA progenitors, and neurons (Pruszak et al., 2007;
Yuan et al., 2011), we isolatedmDA progenitors on differentiation
day 11 andmDA neurons after day 30 (Figure 1B). Prior to FACS,
differentiated culture contained 10%–20% cells with neuronal
identity (Figure 1C). Through capture of CD56+/CD133+ dou-
ble-positive cells, the sample was enriched to contain 90%
mDA progenitors expressing SOX1, SOX2, NESTIN, FOXA2,
and LMX1 (data not shown). Through isolation of CD56+/
CD24+/CD15/CD184 cells, the purity of dopaminergic neu-
rons was increased to 80%, as identified by expression of
TUJ1 and TH. Most importantly, the degree of neuronal enrich-
ment was similar across different cell lines (Figures 1D and 1E).
Postsorting, mDA-related genes of FOXA2, LMX1, TUJ1, TH,
GIRK2, and PITX3 were significantly higher than those of iPSCs,
mDA precursors, and unsorted neurons, indicating an efficientiPSCs
rogenitors and neurons.
opulation (n.s., not significant; n = 3).
ence of TH, FOXA2, and TUJ1.
eurons, and FACS-sorted neurons (n = 3).
GIRK2 to confirm the midbrain dopaminergic lineage on days 36 and 120. The
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Figure 2. a-Synuclein Level Is Higher in GBA N370S Carrier-Derived Neurons
(A) Diagram depicts biochemical assay, immunofluorescence, HPLC, and RNA-seq in FACS-sorted neurons on days 32–34.
(B) GBA protein level was lower in twins carrying GBA N370S (n = 3).
(C) GCase activity (5 3 104 sorts; n = 4) were analyzed at Genzyme Corporation (ANOVA; ***p < 0.001).
(D) a-synuclein protein expression in fibroblasts, iPSCs, and purified mDA progenitors.
(legend continued on next page)
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enrichment for mDA population (Figure 1F). These sorted neu-
rons expressed TUJ1, TH, FOXA2, LMX1, and PITX3 on day 36
(Figure 1G). They were maintained for up to 120 days, still
expressing A9 neuronal marker GIRK2 (Figure 1H). This protocol
allowed us to perform biochemical and functional analysis on
enriched human dopaminergic neurons at uniform purity.
GBA N370S Increases a-Synuclein Levels in iPSC-
Derived mDA Neurons
Mitochondrial abnormalities have been increasingly implicated
in the pathogenesis of PD and have been specifically reported
in the mouse model of Gaucher disease (Osellame et al., 2013)
and dopaminergic neurons with PD-related genetic mutations
(Park et al., 2006; Wood-Kaczmar et al., 2008). Using transmis-
sion electron microscopy, we found that mitochondria in all
differentiated neurons, including GBA N370S mutant mDA neu-
rons, displayed normal morphology and regular distribution in
cytoplasm and processes (Figure S3A). Therewere no significant
differences in cell death in the absence or presence of oxidative
stressors (i.e., rotenone; Figures S3B and S3C). In the high-res-
olution, time-lapse video, the neurite outgrowth rates of both
twins’ neurons were similar (Figure S3D).
FACS-sorted neurons with a heterozygous GBA N370S dis-
played reduced GBA protein levels (Figures 2A and 2B) and
50% GCase activity (Figure 2C) compared to the controls and
PDpatient-derived neuronswithoutGBAmutation. These results
are similar to the findings in postmortem PD human brains car-
rying heterozygousGBAmutations (Gegg et al., 2012). GBAmu-
tations lead to a-synuclein accumulation (Mazzulli et al., 2011),
which prompted us to investigate a-synuclein levels in our co-
horts. Consistent with prior work, a-synuclein was not detectable
in fibroblasts. Fibroblast progeny, including iPSCs andmDA pro-
genitors, expressed a-synuclein. There were no differences be-
tween the monomeric form of a-synuclein across the cell lines
(Figure 2D). Interestingly, when differentiated into mDA neurons,
cell lines harboring GBA N370S had significantly higher a-synu-
clein levels regardless of disease status (Figure 2E), suggesting
that GBA N370S perturbs a-synuclein processing. In contrast,
a-synucleinmRNA leveldidnotdiffer in thesecell lines (Figure2F),
indicating that theGBAmutationdid not interferewitha-synuclein
transcription.Overall, dopaminergicneurons fromboth twinswith
GBAN370Smutation had higher a-synuclein immunoreactivity in
the cell body than the healthy control. In addition, slightly greater
a-synuclein expression was observed in the neurites of dopami-
nergic neurons from the affected compared to the unaffected
twin (Figures 2G and 2H). All these findings support the theory
that GBA N370S may lead to a-synuclein accumulation.
Genetic and Nongenetic Factors Contribute to DA
Levels in Dopaminergic Neurons
We speculated that PD iPSC-derived mDA neurons had an
impaired capacity to synthesize and release DA. To test
this, we performed high-performance liquid chromatography(E and F) a-synuclein protein (E) and RNA (F) expression in sorted mDA neurons
(G and H) Immunofluorescence and quantitation (n R 15 cells, measured for ea
(yellow arrowheads). The scale bar represents 100 mm.
Error bars represent SEM.
Cell Re(HPLC) to measure the intra- and extracellular levels of both
DA and 3,4-dihydroxyphenylacetic acid (DOPAC) (an MAO-
dependent metabolite of DA). The chromatograph peaks of DA
and DOPAC in iPSC-derived mDA neurons were confirmed by
matching the retention times of known standards (Figures 3A
and 3B). L-DOPA (100 mM; 30 min treatment) significantly
increased DA production, indicating that iPSC-derived mDA
neurons quickly converted L-DOPA into DA, which was then
released (Figure 3C). The graph indicated that iPSC-derived
dopaminergic neurons from the GBA-mutated unaffected twin
showed reduced DA production compared to the well-charac-
terized control (C1). In addition, dopaminergic neurons from
the affected twin and the sporadic PD patient displayed lower
intra- and extracellular DA levels (left panels of Figures 3D,
S4A, and S4B). Surprisingly, another subject (C2)—with a family
history of PD—had reduced DA levels, suggesting this patient
has the potential to develop PD, despite the absence of known
genetic PD mutations. To rule out that the control subject’s
(C2) DA level was due to technical variation, we included iPSC
lines from two additional healthy control subjects (C3 and C4)
without a family history of PD. The two controls produced very
similar intra- (6 fmol/mg) and extracellular DA (6 fmol/ml) and
displayed comparable DA:DOPAC ratios as C1 (Figure S4C).
Further investigation revealed the total DA:total DOPAC ratio
was lower in dopaminergic neurons from PD cases than con-
trols. The ratio was notably lower in the affected twin and the
sporadic PD case, indicating elevated MAO activity. Ratios in
all unaffected samples, including C2, were similar (right panels
of Figures 3D, S4A, and S4B).
In addition to the single-cell patch clamp technique, popula-
tion-level electrical activity was measured using multielectrode
arrays (MEAs). Spontaneous activity (isolated single spikes and
multiple-spike bursts) was evident in cultures of neurons by
day 30 (Figure 3E1). Spontaneous activity in mDA neurons
from the affected twin was significantly lower when expressed
as either well-wide spike rate or the number of active electrodes
per well (Figures 3E2 and 3E3), which could arise from either a
cell-autonomous deficiency in excitability or a lack of synaptic
drive from neighboring cells. By day 52, mDA neurons from the
unaffected twin developed robust synchronous bursting pat-
terns indicative of maturing neuronal networks. Although the
firing rate of mDA neurons from the affected twin increased be-
tween days 30 and 52, no synchrony emerged over this period
(Figures 3E2 and 3E3). Taken together, these results illustrate a
delay in the emergence of spontaneous action potentials, and
an absence—or delay to times beyond the course of this exper-
iment—of synchronous activity in the affected twin.
RNA-SeqReveals that ElevatedMAO-BMight Play aRole
in DA Regulation
To explore the pathogenic factors that may explain the clinical
parkinsonism in the affected twin, we investigated the global
transcriptome of iPSCs. RNA-sequencing (RNA-seq) analysis(ANOVA; *p < 0.05; **p < 0.01; n = 3).
ch group) of overall a-synuclein (white arrows) and a-synuclein in the neurites
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Figure 3. Affected Twin-Derived Neurons
Present Lower DA Level and Impaired
Network Activity
(A) A trace of standard chemicals DA and DOPAC
is shown on top for comparison. Representative
HPLC traces of cell lysate (indicative of DA and
DOPAC synthesis) and Tyrode’s buffer (indicative
of DA and DOPAC release).
(B and C) Compiled HPLC data of intra- and
extracellular DA concentrations before (B) and
after (C) supplementing 100 mM L-Dopa.
(D) Compiled HPLC data showed intra- and
extracellular DA (left panels) and DOPAC (middle
panels) concentrations between lines and DA:
DOPAC (right panel) ratios. The lower DA levels
(below the dashed red line) suggested a patho-
logic condition (ANOVA; **p < 0.01; ***p < 0.001;
n = 36).
(E) Multielectrode array in twins. (E1) Raw data
traces for two electrodes from a representative
well. (E2) Spike raster plots on day 30 (top) and 52
(bottom) postplating. (E3) Mean spike rate and
number of active electrodes (n = 4; t test; *p <
0.05).
Error bars represent SEM.showed that there were no differentially expressed genes
between healthy and diseased iPSC lines, displaying nonhierar-
chical clustering (Figure S5A). Next, we examined the global-
gene-expression profiling in FACS-sorted neurons. All R2 corre-
lations between biological replicates were over 0.9, indicating
experimental reproducibility. Looking into the RNA-seq data
for more details on 20 glial genes, we found the canonical glial
markers showed very low expression throughout all 14 iPSC-
derived neuronal samples (Figure S5B), suggesting a consis-
tence of neuronal purification without glial cell contamination.
We initially characterized the expression differences in mDA
neurons from all PD cases (six independent samples) and con-
trols (eight independent samples), identifying 1,028 differentially1178 Cell Reports 9, 1173–1182, November 20, 2014 ª2014 The Authorsexpressed genes making up the PD-
expression signature. Strikingly, MAOB
gene was identified as significantly differ-
entially expressed (p = 0.046). The heat-
map clearly differentiates cases from
controls, where interestingly most differ-
entially expressed genes had lower
expression in PD cases compared to
controls (Figure 4A). In the clustering,
the RNA-expression pattern of the
control (C2) with a family history of PD
located close to the PD-expression
signature suggested a susceptibility to
PD (Figure 4A).
To elucidate expression differences
between twins, we specifically focused
on genes involved in DA synthesis, stor-
age, release/uptake, and PD pathogen-
esis. As seen in Figure 4B, upregulated
MAOB gene expression (+4.19-fold; p =0.0385) stood out in the set with an arbitrary 2-fold change cutoff.
We confirmed the presence of elevated levels of MAOB mRNA
(Figure 4C) and MAO-B protein (Figure 4D) in neurons from
the affected twin. These data suggest that abnormally high
MAOB expression, an additional risk factor to the vulnerable
twin, potentially contributed to the onset of PD in the affected
twin.
Overexpression of GBARescues a-Synuclein Phenotype
and, Together with MAO-B Inhibitor, Promotes DA
Production
To investigate the specificity of GBA mutation on a-synu-
clein level, we overexpressed GBA to compensate for the
Figure 4. MAOB Expression Is Elevated in
PD-iPSC-Derived Neurons
(A) Heatmap shows the global gene-expression
patterns of PD neurons differ from those of a
healthy control (C1) and the unaffected twin (blue
is lower expression and yellow is higher).
(B) A list of genes related with DA synthesis,
uptake/release, metabolism, receptors, and
PD/dopaminergic neurons were differentially ex-
pressed in twins (dark blue, downregulation; red,
upregulation). An asterisk indicates significantly
higher MAOB expression in affected twin (p =
0.0385; n = 4).
(C) The transcriptional abundance of MAOB
across the cohort of patients and controls.
(D) Determination of MAO-B protein in twins’
neurons (t test; *p < 0.05; n = 3).
Error bars represent SEM.deficiency of GBA in the dopaminergic neurons from both
twins by lentivirus infection. Prior to this, we validated the
lentivirus 7.2 wild-type GBA, expressing V5 tag and GBA,
and ensured its high infection efficiency in FACS-sorted
mDA neurons. Three days postinfection, nearly all TH-positive
mDA neurons coexpressed GBA. A remarkable increase of
GBA immunoreactivity was observed in infected cells, but
not in the negative control (Figure 5A). WT GBA overexpres-
sion lowered a-synuclein levels in the GBA N370S twins-
derived neurons (Figure 5B). Concurrently, GBA enzymatic
activities could be significantly rescued compared to unin-
fected neurons (Figure 5C).
Reduced DA level is implicated in GBA mutants regardless of
disease status, especially in PD cases (Figure 3D), indicating
that both genetic and nongenetic effects play a role in DA regu-
lation. We treated twins’ mDA neurons with rasagiline (MAO-B
inhibitor; 20 mM; 24 hr incubation) or WT GBA lentivirus and
observed a slight increase in extracellular DA production in
the affected twin (data not shown). Encouragingly, the combi-
nation of transducing lentivirus carrying WT GBA and adding
rasagiline could elevate DA levels and decrease DOPAC levels
in affected twin’s neurons, similar to the levels of the unaffected
twin. Elevated DA:DOPAC ratios indicated that rasagiline
inhibited MAO-B enzymatic activity (Figure 5D). It appearedCell Reports 9, 1173–1182, Nothat WT GBA and rasagiline indepen-
dently did not alter DA level in the unaf-
fected twin’s neurons. These data sug-
gest the complexity of the mechanisms
involved in the rescue experiment.
DISCUSSION
PD pathogenesis is complex; successful
disease-modifying treatments will require
stratification of genetic and nongenetic
factors. In this proof-of-principle study,
iPSC-derived mDA neurons represent
individual human nerve cells; recapitulate
some key PD pathological features,particularly DA deficiency; and provide a useful model for devel-
oping disease-modifying therapies.
a-Synuclein Accumulation and GBA Mutations
Our discoveries suggest that GBA N370S interferes with a-syn-
uclein clearance. Interestingly, mutated GBA has previously
been shown to cause ER stress and autophagic dysfunctions,
leading to insufficient a-synuclein turnover (Cullen et al., 2011).
In postmortem analysis of PD brains with GBA mutations,
Lewy bodies are immunoreactive for GBA, suggesting that
GBA mutations are sufficient for a-synuclein aggregation
(Goker-Alpan et al., 2010).
a-synuclein aggregation is a pathological hallmark of PD.
Accumulating evidence has identified this phenotype in dopa-
minergic neurons derived from genetic PD patients with SNCA
triplications, GBA N370S/84GG, truncated PARKIN, LRRK2
G2019S, and SNCA A53T (Devine et al., 2011; Imaizumi et al.,
2012; Mazzulli et al., 2011; Nguyen et al., 2011; Ryan et al.,
2013; Sa´nchez-Dane´s et al., 2012). Although we did not observe
differences in the a-synuclein levels between twins harboring
GBA N370S, more a-synuclein was found in the neurites of the
affected twin. This could be due to epigenetic changes of genes
regulating cytoskeletal networks that interfere with a-synuclein
trafficking (Freundt et al., 2012). Consistent with the previousvember 20, 2014 ª2014 The Authors 1179
Figure 5. GBA Overexpression Inhibits
a-Synuclein Level and, Together with
MAO-B Inhibitor, Rescues DA Deficiency
(A) Validation of the infection and specificity of
lentivirus 7.2 WT GBA in the dopaminergic
neurons stained with TH (green) and GBA (red,
arrowheads).
(B) Western blot showed GBA overexpression and
reduced a-synuclein levels in GBA-infected twins’
neurons (t test; ***p < 0.001; n = 3).
(C) Measurement of GCase activity (gray bars,
uninfected cell; green bars, WT GBA; t test; *p <
0.05; **p < 0.01; n = 4 biological).
(D) HPLC analysis revealed change in DA (left),
DOPAC (middle) levels, and DA:DOPAC (right)
ratios before (dotted bars) and after GBA infection
(solid colorful bars; n = 36). The scale bar
represents 100 mm.
Error bars represent SEM.reports on DA neurons with GBA mutations, we observed an
increase in monomeric a-synuclein levels; however, we did
not discover a-synuclein aggregation. In the Gaucher disease
model, neurons with GBA compound heterozygous mutations
N370S/84GG displayed less than 10% GCase activity. In
contrast, neurons derived from twins carrying heterozygous
GBAN370S exhibited an approximately 50%decrease in GCase
activity. Therefore, the severe GBA enzymatic deficiency may be
required for a-synuclein aggregation. This scenario was rein-
forced in the animal model, in which homozygous GBA muta-
tions enhanced a-synuclein aggregations in mouse brains (Sardi
et al., 2011). This implies that additional factors are important for
the synucleinopathy in PD brains carrying heterozygous GBA
mutations.
DA Homeostasis Defects in Neurons from PD Patients
Dopaminergic neurons with Parkin deletions showed enhanced
DA release and maintained the endogenous DA levels (Jiang
et al., 2012). In contrast, neurons with LRRK2 G2019S mutation
demonstrated reduced DA release (Nguyen et al., 2011). These
results suggest that PD-related gene mutations might play
different roles in DA homeostasis. In our study, mDA neurons
carrying GBA N370S showed reduced DA levels, similar to prior
findings of DA neurons with LRRK2 G2019S. How GBA muta-
tions cause reduced DA levels is poorly understood. One possi-
bility is that reduced DA release is secondary to increased
a-synuclein levels. a-synuclein plays a pivotal role in synaptic
vesicle regulation, and overexpressing a-synuclein inhibited1180 Cell Reports 9, 1173–1182, November 20, 2014 ª2014 The AuthorsDA release by 70%–80% in mouse nigral
neurons (Lundblad et al., 2012).
Intriguingly, we found different DA
levels between twins discordant for PD,
suggesting that nongenetic factors could
further perturb DA homeostasis in addi-
tion to GBA mutations. RNA-seq data
indicated that MAOB was highly ex-
pressed in the affected twin, resulting in
an overall decrease in DA levels and alower DA:DOPAC ratio. MAO-B inhibition has been postulated
to be disease-modifying in PD. A clinical trial of a MAO-B inhib-
itor rasagiline has shown promising results on slowing PD pro-
gression (Olanow et al., 2009). It is still unclear how MAO-B level
is upregulated in the affected twin. In schizophrenia, a neuropsy-
chiatric disorder linked to DA dysregulation, hypermethylation of
CpG sites of MAOs has been found in the postmortem brains of
patients (Yang et al., 2012). Further research on the methylation
patterns of CpG sites of MAOs is required to elucidate the epige-
netic changes in the affected twin. Using iPSC-derived neurons
to study epigenetic alterations has drawbacks because the re-
programming process is mostly an epigenetic event and aber-
rant methylation patterns could occur during the reprogramming
and differentiation processes. Despite this caveat, the disease-
relevant epigenetic regulations are conserved during the
neuronal differentiation in the classical epigenetic neurological
disorders (Chamberlain et al., 2010; Yang et al., 2010). In addi-
tion, MAO upregulation has also been found in dopaminergic
neurons from PD patients, suggesting that increasedMAO could
be a common stress response in PD but may also be directly
linked to defective DA regulation.
Improved Neuronal Purification as a Key Step to Cellular
Phenotypes
Reliable production of homogeneous mDA neurons is para-
mount to mechanistic studies and cell-based therapies in PD.
Creating reporter transgenic lines has been proposed as a strat-
egy for mDA neuron enrichment (Ganat et al., 2012), but there is
no consensus on the best promoter and a gene knockin can also
potentially disrupt the recipient’s genome. Given those specific
cell surface markers indicative of developmental stage and line-
age specification (Pruszak et al., 2007), a combination of cell-
surface signatures permits isolation of mDA progenitors and
neurons from the differentiated mixture. The combination of
CD184+/CD271/CD44/CD24+ enables the isolation of mDA
progenitors, and CD184/CD44/CD15LOW/CD24+ defines the
cell-surface-marker signature for the purification of neurons
(Yuan et al., 2011). We isolated CD56+/CD24+/CD15/CD184
population and achieved 80% purity of mDA neurons, thereby
allowing us to perform reliable biochemical and physiological
analysis.
EXPERIMENTAL PROCEDURES
Subjects, Genotyping, and Whole-Exome Sequencing
Seven subjects—a man with a 5-year history of PD (PD-1 and PD-2), his MZ
twin brother without PD (non-PD-1 and non-PD-2), one sporadic PD patient
(sporadic PD-1), and four healthy subjects (C1, C2, C3, and C4)—were re-
cruited for this study (Table S1). DNA from their fibroblasts was extracted for
genotyping and whole-exome sequencing. See Supplemental Information
for more details. Studies were approved by and performed in accordance
with the Western Institutional Review Board and NYU School of Medicine
IRBs.
Transgene-free iPSC Generation, Maintenance, and
Characterization
Using CytoTune iPSC Sendai reprogramming protocol, we converted fibro-
blasts into transgene-free iPSCs. See Supplemental Information for more de-
tails on iPSC generation, maintenance, and characterization.
Midbrain Neuronal Differentiation and Characterization
The differentiation procedure consists of 11-day neural induction and DA
neuronal pattering, as described previously (Kriks et al., 2011). See Supple-
mental Information for more details.
Electrophysiology and Multielectrode Array Recordings
Whole-cell patch clamp was performed on neurons plated on 13 mm plas-
tic coverslips (Thermanox; Thermo) from days 50 to 56. Both twins’ neu-
rons from day 30 and day 52 were plated in four wells each of a 12-well
MEA plate from Axion Biosystems. See Supplemental Information for full
details.
See Supplemental Information for full details regarding immunohistochem-
istry and western blot, fluorescence-activated cell sorting, transmission
electron microscopy, high-performance liquid chromatography, RNA-seq,
real-time PCR assay, and GBA-lentiviral infection.
Statistical Analysis
Statistical analysis was performed using GraphPad Prism v6.0. Data are
described as mean ± SEM. Student’s t test was designed for the comparison
of two groups. One-way ANOVA was applied for multiple comparisons. The
result was considered statistically significant when p < 0.05, 0.01, or 0.001.
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http://dx.doi.org/10.1016/j.celrep.2014.10.023.Cell ReAUTHOR CONTRIBUTIONS
C.M.W., B.A.C., and A.L. designed and performed most of the experiments
and wrote the manuscript. M.J.N. recruited and clinically characterized the
PD patients and edited the manuscript. M.W.N. performed the single-cell
patch clamp and the MEA. M.Z. performed the FACS and analysis. A.L.,
E.V.M., and D.S. analyzed the HPLC data. L.C. performed the PD mutation
genotyping array. E.E.S. and M.R. analyzed the RNA-seq data. S.P.S. and
S.-H.K. performed GCase activity assay and provided lentivirus 7.2 WT
GBA. M.B. analyzed the MEA data. L.R., K.E., S.L., M.R., S.C., S.-H.K., A.L.,
and S.A.N. supervised the project and wrote the manuscript.
ACKNOWLEDGMENTS
We are particularly grateful for the following grant support: Lawrence Golub
and Karen Finerman (NYSCF-Golub Stem Cell Research Initiative for Parkin-
son’s Disease); The Bachmann-Strauss Foundation Research Grant for basic
and clinical research in Parkinson’s disease (to A.L. and S.A.N.); in part by
grant no. PDF-CEI-1414 from the Parkinson’s Disease Foundation (to A.L.);
NIH/NINDS K08NS083738 (to S.-H.K.); Louis V. Gerstner Jr. Scholar Award
(to S.-H.K.); in part by grant no. PDF-CEI-1414 from the Parkinson’s Disease
Foundation (to S.-H.K.); American Academy of Neurology Research Fellow-
ship (to S.-H.K.); NINDS/NIH R01NS075222 (to E.V.M.); and NIH/NIA
(1RF1AG042965-02 and 1U01AG046170-01; to S.A.N.).
Received: May 21, 2014
Revised: September 3, 2014
Accepted: October 10, 2014
Published: November 6, 2014
REFERENCES
Anheim,M., Elbaz, A., Lesage, S., Durr, A., Condroyer, C., Viallet, F., Pollak, P.,
Bonaı¨ti, B., Bonaı¨ti-Pellie´, C., and Brice, A.; French Parkinson Disease Genetic
Group (2012). Penetrance of Parkinson disease in glucocerebrosidase gene
mutation carriers. Neurology 78, 417–420.
Chamberlain, S.J., Chen, P.F., Ng, K.Y., Bourgois-Rocha, F., Lemtiri-Chlieh,
F., Levine, E.S., and Lalande, M. (2010). Induced pluripotent stem cell models
of the genomic imprinting disorders Angelman and Prader-Willi syndromes.
Proc. Natl. Acad. Sci. USA 107, 17668–17673.
Cooper, O., Seo, H., Andrabi, S., Guardia-Laguarta, C., Graziotto, J., Sund-
berg, M., McLean, J.R., Carrillo-Reid, L., Xie, Z., Osborn, T., et al. (2012). Phar-
macological rescue of mitochondrial deficits in iPSC-derived neural cells from
patients with familial Parkinson’s disease. Sci. Transl. Med. 4, 141ra190.
Cullen, V., Sardi, S.P., Ng, J., Xu, Y.H., Sun, Y., Tomlinson, J.J., Kolodziej, P.,
Kahn, I., Saftig, P., Woulfe, J., et al. (2011). Acid b-glucosidase mutants linked
to Gaucher disease, Parkinson disease, and Lewy body dementia alter a-syn-
uclein processing. Ann. Neurol. 69, 940–953.
Devine, M.J., Ryten, M., Vodicka, P., Thomson, A.J., Burdon, T., Houlden, H.,
Cavaleri, F., Nagano, M., Drummond, N.J., Taanman, J.W., et al. (2011).
Parkinson’s disease induced pluripotent stem cells with triplication of the
a-synuclein locus. Nat. Commun. 2, 440.
Do, C.B., Tung, J.Y., Dorfman, E., Kiefer, A.K., Drabant, E.M., Francke, U.,
Mountain, J.L., Goldman, S.M., Tanner, C.M., Langston, J.W., et al. (2011).
Web-based genome-wide association study identifies two novel loci and a
substantial genetic component for Parkinson’s disease. PLoS Genet. 7,
e1002141.
Freundt, E.C., Maynard, N., Clancy, E.K., Roy, S., Bousset, L., Sourigues, Y.,
Covert, M., Melki, R., Kirkegaard, K., and Brahic, M. (2012). Neuron-to-neuron
transmission of a-synuclein fibrils through axonal transport. Ann. Neurol. 72,
517–524.
Ganat, Y.M., Calder, E.L., Kriks, S., Nelander, J., Tu, E.Y., Jia, F., Battista, D.,
Harrison, N., Parmar, M., Tomishima, M.J., et al. (2012). Identification of em-
bryonic stem cell-derived midbrain dopaminergic neurons for engraftment.
J. Clin. Invest. 122, 2928–2939.ports 9, 1173–1182, November 20, 2014 ª2014 The Authors 1181
Gegg, M.E., Burke, D., Heales, S.J., Cooper, J.M., Hardy, J., Wood, N.W., and
Schapira, A.H. (2012). Glucocerebrosidase deficiency in substantia nigra of
parkinson disease brains. Ann. Neurol. 72, 455–463.
Goker-Alpan, O., Stubblefield, B.K., Giasson, B.I., and Sidransky, E. (2010).
Glucocerebrosidase is present in a-synuclein inclusions in Lewy body disor-
ders. Acta Neuropathol. 120, 641–649.
Imaizumi, Y., Okada, Y., Akamatsu, W., Koike, M., Kuzumaki, N., Hayakawa,
H., Nihira, T., Kobayashi, T., Ohyama, M., Sato, S., et al. (2012). Mitochondrial
dysfunction associated with increased oxidative stress and a-synuclein accu-
mulation in PARK2 iPSC-derived neurons and postmortem brain tissue. Mol.
Brain 5, 35.
Jiang, H., Ren, Y., Yuen, E.Y., Zhong, P., Ghaedi, M., Hu, Z., Azabdaftari, G.,
Nakaso, K., Yan, Z., and Feng, J. (2012). Parkin controls dopamine utilization in
humanmidbrain dopaminergic neurons derived from induced pluripotent stem
cells. Nat. Commun. 3, 668.
Kriks, S., Shim, J.W., Piao, J., Ganat, Y.M., Wakeman, D.R., Xie, Z., Carrillo-
Reid, L., Auyeung, G., Antonacci, C., Buch, A., et al. (2011). Dopamine neurons
derived from human ES cells efficiently engraft in animal models of Parkinson’s
disease. Nature 480, 547–551.
Lill, C.M., Roehr, J.T., McQueen, M.B., Kavvoura, F.K., Bagade, S., Schjeide,
B.M., Schjeide, L.M., Meissner, E., Zauft, U., Allen, N.C., et al.; 23andMe
Genetic Epidemiology of Parkinson’s Disease Consortium; International
Parkinson’s Disease Genomics Consortium; Parkinson’s Disease GWAS Con-
sortium; Wellcome Trust Case Control Consortium 2) (2012). Comprehensive
research synopsis and systematic meta-analyses in Parkinson’s disease
genetics: The PDGene database. PLoS Genet. 8, e1002548.
Lundblad, M., Decressac, M., Mattsson, B., and Bjo¨rklund, A. (2012). Impaired
neurotransmission caused by overexpression of a-synuclein in nigral dopa-
mine neurons. Proc. Natl. Acad. Sci. USA 109, 3213–3219.
Marder, K.S., Tang, M.X., Mejia-Santana, H., Rosado, L., Louis, E.D., Comella,
C.L., Colcher, A., Siderowf, A.D., Jennings, D., Nance, M.A., et al. (2010). Pre-
dictors of parkin mutations in early-onset Parkinson disease: the consortium
on risk for early-onset Parkinson disease study. Arch. Neurol. 67, 731–738.
Mazzulli, J.R., Xu, Y.H., Sun, Y., Knight, A.L., McLean, P.J., Caldwell, G.A.,
Sidransky, E., Grabowski, G.A., and Krainc, D. (2011). Gaucher disease gluco-
cerebrosidase and a-synuclein form a bidirectional pathogenic loop in synu-
cleinopathies. Cell 146, 37–52.
Nguyen, H.N., Byers, B., Cord, B., Shcheglovitov, A., Byrne, J., Gujar, P., Kee,
K., Schu¨le, B., Dolmetsch, R.E., Langston, W., et al. (2011). LRRK2 mutant
iPSC-derived DA neurons demonstrate increased susceptibility to oxidative
stress. Cell Stem Cell 8, 267–280.
Olanow, C.W., Rascol, O., Hauser, R., Feigin, P.D., Jankovic, J., Lang, A.,
Langston, W., Melamed, E., Poewe, W., Stocchi, F., and Tolosa, E.; ADAGIO
Study Investigators (2009). A double-blind, delayed-start trial of rasagiline in
Parkinson’s disease. N. Engl. J. Med. 361, 1268–1278.
Osellame, L.D., Rahim, A.A., Hargreaves, I.P., Gegg, M.E., Richard-Londt, A.,
Brandner, S., Waddington, S.N., Schapira, A.H., and Duchen, M.R. (2013).
Mitochondria and quality control defects in a mouse model of Gaucher dis-
ease—links to Parkinson’s disease. Cell Metab. 17, 941–953.
Park, J., Lee, S.B., Lee, S., Kim, Y., Song, S., Kim, S., Bae, E., Kim, J., Shong,
M., Kim, J.M., and Chung, J. (2006). Mitochondrial dysfunction in Drosophila
PINK1 mutants is complemented by parkin. Nature 441, 1157–1161.1182 Cell Reports 9, 1173–1182, November 20, 2014 ª2014 The AutPruszak, J., Sonntag, K.C., Aung, M.H., Sanchez-Pernaute, R., and Isacson,
O. (2007). Markers and methods for cell sorting of human embryonic stem
cell-derived neural cell populations. Stem Cells 25, 2257–2268.
Reinhardt, P., Schmid, B., Burbulla, L.F., Scho¨ndorf, D.C., Wagner, L., Glatza,
M., Ho¨ing, S., Hargus, G., Heck, S.A., Dhingra, A., et al. (2013). Genetic correc-
tion of a LRRK2 mutation in human iPSCs links parkinsonian neurodegenera-
tion to ERK-dependent changes in gene expression. Cell Stem Cell 12,
354–367.
Ryan, S.D., Dolatabadi, N., Chan, S.F., Zhang, X., Akhtar, M.W., Parker, J.,
Soldner, F., Sunico, C.R., Nagar, S., Talantova, M., et al. (2013). Isogenic
human iPSC Parkinson’s model shows nitrosative stress-induced dysfunction
in MEF2-PGC1a transcription. Cell 155, 1351–1364.
Salti, A., Nat, R., Neto, S., Puschban, Z., Wenning, G., and Dechant, G. (2013).
Expression of early developmental markers predicts the efficiency of embry-
onic stem cell differentiation into midbrain dopaminergic neurons. Stem Cells
Dev. 22, 397–411.
Sa´nchez-Dane´s, A., Richaud-Patin, Y., Carballo-Carbajal, I., Jime´nez-Del-
gado, S., Caig, C., Mora, S., Di Guglielmo, C., Ezquerra, M., Patel, B., Giralt,
A., et al. (2012). Disease-specific phenotypes in dopamine neurons from hu-
man iPS-based models of genetic and sporadic Parkinson’s disease. EMBO
Mol. Med. 4, 380–395.
Sardi, S.P., Clarke, J., Kinnecom, C., Tamsett, T.J., Li, L., Stanek, L.M., Pas-
sini, M.A., Grabowski, G.A., Schlossmacher, M.G., Sidman, R.L., et al.
(2011). CNS expression of glucocerebrosidase corrects alpha-synuclein
pathology andmemory in amousemodel of Gaucher-related synucleinopathy.
Proc. Natl. Acad. Sci. USA 108, 12101–12106.
Sidransky, E., Nalls, M.A., Aasly, J.O., Aharon-Peretz, J., Annesi, G., Barbosa,
E.R., Bar-Shira, A., Berg, D., Bras, J., Brice, A., et al. (2009). Multicenter anal-
ysis of glucocerebrosidase mutations in Parkinson’s disease. N. Engl. J. Med.
361, 1651–1661.
Tanner, C.M., Ottman, R., Goldman, S.M., Ellenberg, J., Chan, P., Mayeux, R.,
and Langston, J.W. (1999). Parkinson disease in twins: an etiologic study.
JAMA 281, 341–346.
Wirdefeldt, K., Gatz, M., Reynolds, C.A., Prescott, C.A., and Pedersen, N.L.
(2011). Heritability of Parkinson disease in Swedish twins: a longitudinal study.
Neurobiol. Aging 32, 1923.e1–1923.e8.
Wood-Kaczmar, A., Gandhi, S., Yao, Z., Abramov, A.Y., Miljan, E.A., Keen, G.,
Stanyer, L., Hargreaves, I., Klupsch, K., Deas, E., et al. (2008). PINK1 is neces-
sary for long term survival and mitochondrial function in human dopaminergic
neurons. PLoS ONE 3, e2455.
Yang, Y., Gozen, O., Vidensky, S., Robinson, M.B., and Rothstein, J.D. (2010).
Epigenetic regulation of neuron-dependent induction of astroglial synaptic
protein GLT1. Glia 58, 277–286.
Yang, Q., Ikemoto, K., Nishino, S., Yamaki, J., Kunii, Y., Wada, A., Homma, Y.,
and Niwa, S. (2012). DNA methylation of the Monoamine Oxidases A and B
genes in postmortem brains of subjects with schizophrenia. Open Journal of
Psychiatry 2, 374–383.
Yuan, S.H., Martin, J., Elia, J., Flippin, J., Paramban, R.I., Hefferan, M.P., Vidal,
J.G., Mu, Y., Killian, R.L., Israel, M.A., et al. (2011). Cell-surface marker signa-
tures for the isolation of neural stem cells, glia and neurons derived from
human pluripotent stem cells. PLoS ONE 6, e17540.hors
